September 16, 2020
Taiwan-based digital health startup Health2Sync has entered into a partnership with pharma giant Sanofi with the aim to apply the digital solution provided by Health2Sync in 300 clinics and hospitals nationwide certified by Taiwan Diabetes Shared Care Network over the next three years.
As part of the partnership, Health2Sync will provide patient management software for healthcare professionals...
August 24, 2020
Today One Drop announced a string of new deals with Bayer that could bring the digital diabetes-management company nearly $100 million in new funds.
The agreements include the closure of a Series C financing round led by the pharma giant, as well as $64 million in unspecified development commitments and potential commercial milestone payments.
Launched in late 2016, One Drop's wireless blood...
August 18, 2020
Cecelia Health, a virtual diabetes and chronic disease management startup, has raised $13 million in Series B funding. Rittenhouse Ventures and Endo Investors co-led the round, which also saw participation from Boston Millennia Partners, SustainVC, G100 Capital and others.
WHAT IT DOES
The company was initially founded as Fit4D, and focused on access to certified diabetes educators (CDE) for...
August 11, 2020
Continuous glucose monitoring (CGM) system-maker Senseonics has cut a deal with Ascensia Diabetes Care and its parent company, PHC Holdings, outlining commercialization and distribution of the Eversense product line over the next few years.
According to the companies, Ascensia now holds exclusive global distribution rights for the Eversense, Eversense XL and future CGMs. The duration of the...
July 29, 2020
A retrospective analysis of more than 2,000 Livongo Diabetes Prevention Program (DPP) participants found an average weight loss of 5.1% from baseline after 12 months, and 6.6% among those who designated as high engagers.
The study, conducted by Livongo and published in BMJ Open Diabetes Research & Care, honed in on the relationships between specific program behaviors and program engagement...
July 13, 2020
UnitedHealth Group announced plans this morning to distribute a device-driven diabetes management model to 230,000 employer-sponsored members with Type 2 diabetes at no additional cost.
The pilot program, called Level2 by UnitedHealthcare, provides members with a Dexcom G6 continuous glucose monitor (CGM) that connects to their smartphone, a Fitbit activity tracker, personalized coaching and...
June 15, 2020
The American Diabetes Association's 80th Scientific Sessions kicked off this weekend, and a handful of diabetes management device-makers and service providers highlighted new data as part of the virtual clinical conference. Read on for summaries of the studies and findings, as well as links to the online abstracts.
Verily-backed diabetes management service Onduo, which combines a mobile app...
June 9, 2020
A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional fingerstick testing.
Abbott’s system uses flash continuous glucose monitoring (CGM) through a sensor placed to the back of the upper arm, and lasts for up to 14 days. The device automatically collects...
April 21, 2020
Digital diabetes-management company One Drop announced last week that it has acquired the assets, IP and certain staff of Sano Intelligence, the maker of a non-invasive connected CGM patch. The terms of this asset purchase were not disclosed.
Sano was founded in 2011, and over the course of the decade raised approximately $20 million from investors such as Fitbit, Intel Capital, True Ventures and...
March 12, 2020
Together in perfect harmony. Dexcom and Welldoc have kicked off a new collaboration that will provide Dexcom G6 continuous glucose monitor users with data-analysis insights from Welldoc's digital diabetes management product, BlueStar. These insights include information on how lifestyle factors such as activity, nutrition, sleep and medication adherence are affecting a user's glucose levels.